Final Glance: Biotechnology companies
AP - Thu Oct 16, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)
Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C
CNW Group - Thu Oct 16, 1:44PM CDT
-- Harvoni Provides High Cure Rates (SVR12), Shortens Treatment Duration and Eliminates Need for Interferon and Ribavirin --
GILD: 96.88 (+0.72)
Health Canada Issues Notice of Compliance for Gilead's Harvoni(TM) (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Business Wire - Thu Oct 16, 12:30PM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Harvoni(TM) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single table regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, granted marketing authorization under the tradename Sovaldi(R) in December 2013. The efficacy of Harvoni has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naive patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.
GILD: 96.88 (+0.72)
Midday Glance: Biotechnology companies
AP - Thu Oct 16, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)
Early Glance: Biotechnology companies
AP - Thu Oct 16, 10:35AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 96.88 (+0.72), AMGN: 130.45 (-0.45), CELG: 86.38 (-0.17)
3 Reasons AbbVie's Stock Could Rise
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 16, 7:02AM CDT
Finding reasons to worry about AbbVie 's stock isn't too hard these days. Shares have dropped over 7% in the last few weeks -- and that was before the latest cause for uneasiness. The pharmaceutical company's board just announced that it is...
GILD: 96.88 (+0.72), SHPG: 178.46 (+7.97), ABBV: 52.90 (-1.73)
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 92.54 (+2.91), EBS: 21.24 (+0.35), GILD: 96.88 (+0.72), NVAX: 5.16 (+0.47)
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 101.26 (+0.16), ALNY: 84.94 (+0.55), GILD: 96.88 (+0.72), SRPT: 22.30 (+1.39), AUXL: 30.35 (-0.06), AMGN: 130.45 (-0.45), ABBV: 52.90 (-1.73)
Should Gilead Sciences, inc. Fear Incoming Competition?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 12:17PM CDT
Gilead Sciences ' shares have tumbled more than 8% in the past week as investors digest the FDA approval of its second-generation hepatitis C drug Harvoni and the potential competitive threats from AbbVie and Bristol-Myers Squibb . ...
GILD: 96.88 (+0.72), ABBV: 52.90 (-1.73), BMY: 49.22 (+0.26)
Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary
Sweta Killa - ZACKS - Wed Oct 15, 12:00PM CDT
Investors should take a close look to healthcare ETFs following Johnson & Johnson earnings beat.
JNJ: 96.78 (-1.43), PPH: 58.24 (-0.34), IYH: 126.91 (-0.17), GILD: 96.88 (+0.72), ABBV: 52.90 (-1.73), XLV: 60.21 (-0.31)
Jim Cramer on Stocks and Investing: Why I Hate This Market
at The Street - Wed Oct 15, 10:21AM CDT
Because it’s completely hit or miss.
JNJ: 96.78 (-1.43), SWKS: 51.53 (+1.93), GILD: 96.88 (+0.72), DOW: 44.76 (+0.67)
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
at The Street - Wed Oct 15, 8:35AM CDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
SGEN: 34.73 (+1.40), GILD: 96.88 (+0.72)
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 226.35 (-3.35), GILD: 96.88 (+0.72), DDD: 40.90 (-0.37), TKMR: 22.81 (-1.09), TASR: 14.97 (+0.28)
'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks
at The Street - Wed Oct 15, 4:00AM CDT
The trading panel discussed whether margin calls are weighing on the energy sector and which technology stocks to consider.
F: 13.98 (+0.36), SWKS: 51.53 (+1.93), AMGN: 130.45 (-0.45), SOXX: 77.60 (+1.18), INTC: 30.85 (-0.42), PANW: 97.88 (+0.45), JNPR: 19.19 (+0.06), COH: 35.12 (-0.42), EBAY: 47.88 (-2.36), GILD: 96.88 (+0.72), GWPH: 63.09 (+1.54), DPZ: 83.93 (+0.28), GOOGL: 536.92 (-3.81), CP: 193.81 (+6.69), MELI: 105.94 (-0.22), CSCO: 22.82 (-0.14), KING: 11.31 (-0.07)
J&J raises outlook on Q3 beat
at Investor's Business Daily - Tue Oct 14, 5:51PM CDT
The medical giant's earnings, ex items, rose 10% to $1.50 a share, beating analysts' estimates by 5 cents. Sales climbed 5% to $18.47 bil, $90 mil ahead of consensus. Johnson & Johnson (JNJ) raised its full-year EPS guidance to $5.92-$5.97, on the...
JNJ: 96.78 (-1.43), GILD: 96.88 (+0.72)
Gilead
at Investor's Business Daily - Tue Oct 14, 5:49PM CDT
Gilead (GILD) shares fell 4.2% to 97.18 as light sales of J&J's Olysio could imply that Sovaldi sales may also come in light. Comments by J&J executives that they will work to make Olysio accessible and competitive in light of the recent approval of...
GILD: 96.88 (+0.72)
Wall Street Ends Mixed; Airlines Soar As Oil Plunges
at Investor's Business Daily - Tue Oct 14, 4:09PM CDT
Stocks ended mixed Tuesday after trimming early gains. Volume crept higher. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2%, and the Dow Jones industrial average slipped a fraction. Preliminary data showed that volume rose slightly on the NYSE and the...
NFLX: 361.70 (-86.89), SWKS: 51.53 (+1.93), GILD: 96.88 (+0.72), DAL: 33.32 (+0.94), DPZ: 83.93 (+0.28), BAC: 16.08 (+0.32), SCHW: 25.50 (+0.18), URI: 99.64 (+6.21), LUV: 30.94 (+0.92)